Joel W. Hay

Inflammatory bowel disease : costs-of-illness

We have evaluated the economic costs to society for the two major types of inflammatory bowel disease, Crohns disease and ulcerative colitis, using a medical decision algorithm costing methodology augmented by examination of 1988–89 claims data from a major U.S. commercial insurer. The average annual medical cost per patient with Crohns disease was estimated at

Effectiveness of a lifestyle intervention in promoting the well-being of independently living older people: results of the Well Elderly 2 Randomised Controlled Trial

6,561 (1990 U.S. dollars). The total annual medical costs for U.S. Crohns disease patients in 1990 was estimated at

The economic costs of Alzheimer's disease.

1.0–1.2 billion. The average annual medical cost per patient with ulcerative colitis was estimated at

Cost-Effectiveness of Pravastatin in Secondary Prevention of Coronary Artery Disease *

1,488. The total annual medical costs for U.S. patients with ulcerative colitis in 1990 was estimated at

Cost‐Effectiveness of Preventive Occupational Therapy for Independent‐Living Older Adults

0.4–0.6 billion. Adjusting for productivity losses, we estimated the annual economic cost for both diseases at

Pharmacoeconomics of Lipid-Lowering Agents for Primary and Secondary Prevention of Coronary Artery Disease

1.8 billion to

Physician-induced demand: An empirical analysis of the consumer information gap☆

2.6 billion. Analysis of insurance claims data for inflammatory bowel disease patients showed that the distribution of annual medical expenses charged and paid is highly uneven by patient. The top 2% of Crohns disease patients accounted for 28.9% of total charges and 34.3% of the total amount paid. The top 2% of ulcerative colitis patients accounted for 36.2% of total charges and 39.0% of the total amount paid. We used a multivariate regression model to examine potential cost-effectiveness tradeoffs between different types of medical services in treatment of inflammatory bowel disease.

Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis

Background Older people are at risk for health decline and loss of independence. Lifestyle interventions offer potential for reducing such negative outcomes. The aim of this study was to determine the effectiveness and cost-effectiveness of a preventive lifestyle-based occupational therapy intervention, administered in a variety of community-based sites, in improving mental and physical well-being and cognitive functioning in ethnically diverse older people. Methods A randomised controlled trial was conducted comparing an occupational therapy intervention and a no-treatment control condition over a 6-month experimental phase. Participants included 460 men and women aged 60–95 years (mean age 74.9±7.7 years; 53% <

Cost-Effectiveness Analysis of Collaborative Care Management of Major Depression among Low-Income, Predominantly Hispanics with Diabetes

12 000 annual income) recruited from 21 sites in the greater Los Angeles metropolitan area. Results Intervention participants, relative to untreated controls, showed more favourable change scores on indices of bodily pain, vitality, social functioning, mental health, composite mental functioning, life satisfaction and depressive symptomatology (ps<0.05). The intervention group had a significantly greater increment in quality-adjusted life years (p<0.02), which was achieved cost-effectively (US

Asthma costs and utilization in a managed care organization

41 218/UK £24 868 per unit). No intervention effect was found for cognitive functioning outcome measures. Conclusions A lifestyle-oriented occupational therapy intervention has beneficial effects for ethnically diverse older people recruited from a wide array of community settings. Because the intervention is cost-effective and is applicable on a wide-scale basis, it has the potential to help reduce health decline and promote well-being in older people. Trial Registration clinicaltrials.gov identifier: NCT0078634.